INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morgan Stanley and Encourages Investors with Losses to Contact the Firm
April 12, 2024 10:24 ET
|
Schall Law
The Schall Law Firm Announces it is Investigating Claims Against Morgan Stanley and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Morgan Stanley Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 11, 2024 15:44 ET
|
Block & Leviton LLP
BOSTON, April 11, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Morgan Stanley (NYSE: MS) for potential securities law violations. Investors who have lost money in their Morgan...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024 09:30 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023 07:09 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Study: Brain Training Improves Cognitive Function In Multiple Sclerosis
November 06, 2023 07:59 ET
|
Posit Science
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- A study conducted at the University of Nebraska Medical Center showed use of a commercially-available brain training app significantly improved...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
August 01, 2023 12:02 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...